Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Change in Accured Expenses for 18 consecutive years, with $61.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 61.06% year-over-year to $61.6 million; the trailing twelve-month figure through Jun 2026 stood at -$39.8 million (down 281.27% YoY), and the FY2025 full-year result was $75.1 million, down 17.59% from the prior year.
• Change in Accured Expenses grew to $61.6 million in Q2 2026 per ALNY's latest filing, from -$176.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $249.4 million in Q3 2025 and bottomed at -$176.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $18.0 million across 5 years, with a median of $64.9 million in 2022.
• The widest YoY moves for Change in Accured Expenses: up 198.38% in 2025, down 3142.24% in 2025.
• Over 5 years, Change in Accured Expenses stood at $102.6 million in 2022, then sank by 137.68% to -$38.7 million in 2023, then plunged by 60.62% to -$62.1 million in 2024, then slumped by 181.54% to -$174.9 million in 2025, then jumped by 135.24% to $61.6 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $61.6 million, -$176.0 million, and -$174.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.